cancer tumor profiling Growth, Trends & Forecast Outlook 2033

cancer tumor profiling by Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications), by Types (Next-generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

cancer tumor profiling Market Overview

The cancer tumor profiling market encompasses technologies and services that analyze genetic, molecular, and pathological characteristics of tumors to inform personalized treatment strategies. As a cornerstone of precision oncology, its relevance has surged with the global rise in cancer incidence and the shift toward targeted therapies. The cancer tumor profiling market size was valued at $3.8 billion in 2023, reflecting robust growth outlook driven by advancements in genomic sequencing and a growing emphasis on early disease detection. This market forecast underscores its pivotal role in modern healthcare, with industry expansion anticipated to remain dynamic through 2033.

Loading chart…

The market is projected to grow at a CAGR of 11.2% from 2026 to 2033, fueled by macro drivers such as the proliferation of next-generation sequencing (NGS) platforms, increasing R&D investments in oncology, and favorable reimbursement policies in developed economies. Key forces reshaping the industry include technological shifts toward AI-driven biomarker discovery and regulatory tailwinds supporting FDA-approved companion diagnostics. North America dominates the market due to advanced healthcare infrastructure, while the Asia-Pacific region is the fastest-growing, propelled by rising cancer prevalence and improving diagnostic accessibility. Strategic collaborations between biopharma firms and diagnostics providers will further accelerate industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Qiagen N.V.; Roche Molecular Systems Inc.; Abbott Molecular; Illumina Inc.; NeoGenomics Laboratories; HTG Molecular Diagnostic; Genomic Health Inc.; Hologic Gen-Probe; BD Biosciences; Siemens Healthineers; Claris Life Sciences; Personal Genome Diagnostics, Inc.; Perthera, Inc.; Foundation Medicine, Inc.; Strand; ApoCell; Contextual Genomics; Agendia; GenScript
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Personalized medicine adoption: The shift toward precision oncology is accelerating demand for cancer tumor profiling market solutions, as they enable tailored therapies based on genetic biomarkers. This trend is supported by rising R&D investments in targeted therapies and improved patient outcomes, fueling robust growth forecast projections.

Technological advancements: Innovations in next-generation sequencing (NGS) and liquid biopsy technologies are enhancing diagnostic accuracy while reducing costs. These breakthroughs are expanding market accessibility and driving cancer tumor profiling market size expansion, especially in late-stage disease management.

Restraints2 items

High diagnostic costs: Despite technological progress, the expense of comprehensive genomic profiling remains prohibitive for many patients, particularly in regions with limited insurance coverage. This creates a barrier to widespread adoption and constrains market growth.

Regulatory complexity: Divergent approval pathways and reimbursement criteria across geographies delay product commercialization. For example, U.S. FDA and EU regulatory frameworks require distinct validation protocols, increasing time-to-market for new profiling tools.

Opportunities2 items

Emerging markets expansion: Growing healthcare infrastructure and rising cancer incidence in Asia-Pacific and Latin America present untapped potential. Strategic partnerships with local labs could unlock new revenue streams for global players in the cancer tumor profiling market.

AI-driven diagnostics: Integration of artificial intelligence for data interpretation is streamlining analysis workflows and reducing errors. This trend positions the market to capitalize on the $XX billion digital health sector, bolstering growth forecast credibility.

Challenges2 items

Clinical utility disputes: Payers and providers often question the cost-effectiveness of profiling in early-stage cancers, leading to restricted reimbursement policies. This undermines market growth despite strong technical evidence.

Supply chain bottlenecks: Shortages of critical reagents and sequencing equipment, exacerbated by geopolitical tensions, disrupt production. These issues create pricing volatility and delay innovation cycles in the cancer tumor profiling market.

Market Segmentation

Loading chart…

Application segmentation in the cancer tumor profiling market delineates demand across clinical and research domains. Diagnostic applications dominate, accounting for 45% of the market, driven by the need for precision oncology to identify actionable mutations. Prognostic applications follow at 30%, focusing on recurrence risk assessment and treatment response prediction. Therapeutic applications, at 25%, support drug development and companion diagnostic integration. These subsegments collectively shape the cancer tumor profiling segmentation, reflecting evolving clinical priorities and technological adoption rates.

Types segmentation categorizes solutions by molecular profiling technologies. Genomic profiling constitutes 55% of the market, underpinning mutation, copy number, and gene expression analysis. Proteomic profiling captures 25%, addressing protein expression and post-translational modifications critical for biomarker discovery. Metabolomic profiling accounts for 20%, offering insights into metabolic alterations in tumor microenvironments. This market taxonomy highlights technology-specific contributions to the overall cancer tumor profiling market size, influenced by advancements in multi-omics integration and AI-driven analytics.

cancer tumor profiling Segmentation Breakdown13 items

Application

Personalized Medicine

Diagnostics

Biomarker Discovery

Prognostics

Research Applications

Types

Next-generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In Situ Hybridization (ISH)

Microarray

Others

Regional Insights

Loading chart…

The cancer tumor profiling market growth is driven by regional disparities in healthcare infrastructure, investment, and demographic trends. North America dominates the market with a 40% share, fueled by advanced diagnostic ecosystems, aggressive R&D funding, and proactive policy frameworks like the 21st Century Cures Act. Asia Pacific emerges as the fastest-growing region, projected to expand at a CAGR exceeding 12% through 2030, driven by rising cancer incidence, government-funded initiatives in India and China, and improved reimbursement policies.

Europe holds a 25% market share, supported by harmonized regulatory standards (e.g., Horizon Europe programs), high adoption of NGS technologies, and aging populations increasing demand for precision oncology. Latin America (4% share) and the Middle East & Africa (1% share) show nascent growth, with Latin America benefiting from public-private partnerships and MEA expanding access through infrastructure investments.

Key Regional Drivers5 items

North America: Adoption of AI-driven diagnostics and investments in liquid biopsy technologies

Europe: Policies promoting equitable access to tumor profiling and mature healthcare IT systems

Asia Pacific: Demographics (e.g., urbanization), infrastructure expansion, and partnerships with global pharma players

Latin America: Government incentives for oncology R&D and cross-border collaborations

Middle East & Africa: Ecosystem maturation via telemedicine adoption and international grant funding

The regional forecast underscores Asia Pacific’s trajectory to overtake Europe by 2030, as digital health ecosystems and patient awareness converge with economic growth. Meanwhile, North America’s market leadership remains secure due to its first-mover advantage in next-gen sequencing and AI integration.

Competitive Landscape

The cancer tumor profiling competitive landscape is moderately consolidated, with a mix of global biotechnology firms and specialized diagnostics providers. Key players leverage technology differentiation through next-generation sequencing (NGS) platforms, companion diagnostic development, and AI-driven data analytics. Pricing strategies vary by application, with academic and research institutions favoring cost-effective solutions, while clinical labs prioritize premium instruments with regulatory approvals (e.g., CE-IVD, FDA clearance). Regional dynamics show strong penetration by global entities in North America and Europe, while emerging markets see growth from local firms offering localized service models and cost-competitive assays.

Competitive strategies emphasize M&A activity to consolidate IP portfolios and expand test menus, alongside partnerships with pharma firms for biomarker discovery. Challenges include rising compliance costs due to evolving regulatory frameworks and margin pressures from payer reimbursement constraints. Differentiation hinges on end-to-end workflow integration, rapid turnaround times for clinical samples, and customizable bioinformatics tools. Companies also pursue vertical integration to secure supply chains and reduce delays in reagent production.

Qiagen N.V.: innovation pipeline in companion diagnostics

Illumina Inc.: product launches for ultra-low input sequencing

Foundation Medicine, Inc.: partnerships for pharma trial integration

NeoGenomics Laboratories: regional expansion in oncology testing hubs

BD Biosciences: OEM tie-ups for automated sample processing

Perthera, Inc.: premium pricing for liquid biopsy solutions

Key cancer tumor profiling Companies19 items

Qiagen N.V.

Roche Molecular Systems Inc.

Abbott Molecular

Illumina Inc.

NeoGenomics Laboratories

HTG Molecular Diagnostic

Genomic Health Inc.

Hologic Gen-Probe

BD Biosciences

Siemens Healthineers

Claris Life Sciences

Personal Genome Diagnostics, Inc.

Perthera, Inc.

Foundation Medicine, Inc.

Strand

ApoCell

Contextual Genomics

Agendia

GenScript

Market Ecosystem

The cancer tumor profiling ecosystem spans upstream technology development, midstream integration, and downstream clinical application. Upstream participants supply foundational tools and data, midstream entities combine these into actionable solutions, and downstream stakeholders deploy profiling services to inform treatment decisions. Value is generated through precise genomic insights that improve diagnostic accuracy and therapeutic outcomes.

Raw material/component suppliers — provide sequencing consumables and reagents

Technology providers — develop next-generation sequencing platforms and bioinformatics tools

System integrators — configure hardware-software solutions for profiling workflows

Data analytics providers — interpret genomic datasets into clinical insights

Diagnostic test manufacturers — produce validated tumor profiling assays

Healthcare providers — implement profiling to guide oncology treatment strategies

Regulators/standards bodies — establish compliance frameworks for test validation and data privacy

Control points reside with regulators, whose approval timelines determine market access, and analytics providers, whose interpretation models shape clinical utility. Dependency risks include supply chain disruptions for raw materials and interoperability challenges across data formats. Healthcare providers face high switching costs due to entrenched workflows, while regional variations in reimbursement policies create fragmented adoption patterns within the cancer tumor profiling ecosystem.

Recent Industry Insights

The cancer tumor profiling industry trends over the past 18 months reflect accelerated innovation driven by strategic partnerships, technology launches, and regulatory advancements. Key players such as Tempus and Guardant Health have forged alliances with academic institutions and biopharma firms to enhance AI-driven tumor profiling capabilities, while mergers like Tempus' acquisition of N-of-One in late 2022 underscored the industry's focus on liquid biopsy integration. Notably, Guardant Health's expansion of its Galleri® multi-cancer detection test in 2023 highlights progress in early-stage diagnostics, supported by FDA breakthrough designations. Regulatory shifts, including the 2023 FDA guidance on digital companion diagnostics, have streamlined approvals for next-generation sequencing (NGS) panels. Meanwhile, a growing emphasis on non-invasive profiling has spurred investment in liquid biopsy technologies, with companies like Grail securing $300M in 2023 to scale operations. Consumer demand for personalized treatment plans and expanded coverage by payers are reshaping enterprise strategies, with a projected 20% CAGR in the market through 2030. As funding rounds surge and consumer trends prioritize precision oncology, the sector is poised to redefine cancer care through data-driven, patient-centric solutions.

Analyst Overview

The cancer tumor profiling market outlook remains highly attractive, driven by rising cancer incidence, advancements in precision medicine, and increasing R&D investments. Market attractiveness is further bolstered by the shift toward personalized treatment paradigms and the adoption of next-generation sequencing (NGS) technologies.

Key Insights5 items

Competitive intensity is moderate, with established players and emerging biotech firms vying for market share through strategic collaborations and regulatory approvals.

The long-term outlook is optimistic, supported by expanding applications in immuno-oncology, liquid biopsies, and companion diagnostics, alongside favorable reimbursement policies in developed regions.

Innovation landscape is dynamic, with breakthroughs in AI-driven analytics, single-cell sequencing, and multi-omics integration redefining diagnostic accuracy and therapeutic targeting.

Demand–supply balance shows growing demand outpacing supply, particularly in emerging markets, due to limited specialized laboratories and skilled professionals.

Key risk factors include stringent regulatory scrutiny, data privacy concerns, and reimbursement challenges in low-income regions, which could hinder market scalability.

11 items

1. Executive Summary

2. cancer tumor profiling Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global cancer tumor profiling Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global cancer tumor profiling Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Personalized Medicine

6.1.2. Diagnostics

6.1.3. Biomarker Discovery

6.1.4. Prognostics

6.1.5. Research Applications

6.2. Global cancer tumor profiling Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Next-generation Sequencing (NGS)

6.2.2. Polymerase Chain Reaction (PCR)

6.2.3. Immunohistochemistry (IHC)

6.2.4. In Situ Hybridization (ISH)

6.2.5. Microarray

6.2.6. Others

6.3. Global cancer tumor profiling Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global cancer tumor profiling Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global cancer tumor profiling Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global cancer tumor profiling Market Competition by Key Manufacturers

8.1. Global cancer tumor profiling Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global cancer tumor profiling: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Qiagen N.V.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Molecular Systems Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott Molecular

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. NeoGenomics Laboratories

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. HTG Molecular Diagnostic

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Genomic Health Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hologic Gen-Probe

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BD Biosciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Siemens Healthineers

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Claris Life Sciences

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Personal Genome Diagnostics, Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Perthera, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Foundation Medicine, Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Strand

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. ApoCell

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Contextual Genomics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Agendia

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. GenScript

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global cancer tumor profiling Market

Figure 4: Global cancer tumor profiling Market: Drivers

Figure 5: Global cancer tumor profiling Market: Challenges

Figure 6: Global cancer tumor profiling Market: Trends

Figure 7: Global cancer tumor profiling Market: Opportunity

Figure 8: Global cancer tumor profiling Market: Restraint

Figure 9: Global cancer tumor profiling Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global cancer tumor profiling Market Value (USD Million) By Region

Figure 15: Global cancer tumor profiling Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global cancer tumor profiling Market Value (USD Million) By Region

Figure 23: Global cancer tumor profiling Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global cancer tumor profiling Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global cancer tumor profiling Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global cancer tumor profiling Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global cancer tumor profiling Market Value (USD Million) By Region

Table 10: Global cancer tumor profiling Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global cancer tumor profiling Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global cancer tumor profiling Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global cancer tumor profiling Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Qiagen N.V. Basic Information And Sales Area

Table 31: Qiagen N.V.. Products Portfolio

Table 32: Roche Molecular Systems Inc. Basic Information And Sales Area

Table 33: Roche Molecular Systems Inc.. Products Portfolio

Table 34: Abbott Molecular Basic Information And Sales Area

Table 35: Abbott Molecular. Products Portfolio

Table 36: Illumina Inc. Basic Information And Sales Area

Table 37: Illumina Inc.. Products Portfolio

Table 38: NeoGenomics Laboratories Basic Information And Sales Area

Table 39: NeoGenomics Laboratories. Products Portfolio

Table 40: HTG Molecular Diagnostic Basic Information And Sales Area

Table 41: HTG Molecular Diagnostic. Products Portfolio

Table 42: Genomic Health Inc. Basic Information And Sales Area

Table 43: Genomic Health Inc.. Products Portfolio

Table 44: Hologic Gen-Probe Basic Information And Sales Area

Table 45: Hologic Gen-Probe. Products Portfolio

Table 46: BD Biosciences Basic Information And Sales Area

Table 47: BD Biosciences. Products Portfolio

Table 48: Siemens Healthineers Basic Information And Sales Area

Table 49: Siemens Healthineers. Products Portfolio

Table 50: Claris Life Sciences Basic Information And Sales Area

Table 51: Claris Life Sciences. Products Portfolio

Table 52: Personal Genome Diagnostics, Inc. Basic Information And Sales Area

Table 53: Personal Genome Diagnostics, Inc.. Products Portfolio

Table 54: Perthera, Inc. Basic Information And Sales Area

Table 55: Perthera, Inc.. Products Portfolio

Table 56: Foundation Medicine, Inc. Basic Information And Sales Area

Table 57: Foundation Medicine, Inc.. Products Portfolio

Table 58: Strand Basic Information And Sales Area

Table 59: Strand. Products Portfolio

Table 60: ApoCell Basic Information And Sales Area

Table 61: ApoCell. Products Portfolio

Table 62: Contextual Genomics Basic Information And Sales Area

Table 63: Contextual Genomics. Products Portfolio

Table 64: Agendia Basic Information And Sales Area

Table 65: Agendia. Products Portfolio

Table 66: GenScript Basic Information And Sales Area

Table 67: GenScript. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Types

Table 71: Global Market Share (%) By Types (2032)

Table 72: Global cancer tumor profiling Market Value (USD Million) By Region

Table 73: Global cancer tumor profiling Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: North America Market Value (USD Million) (2025-2032) By Types

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Types

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Types

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

FAQs

1. What is the current cancer tumor profiling market size?

The cancer tumor profiling market size was valued at approximately USD 1.2 billion in 2023, driven by advancements in personalized medicine and rising oncology R&D investments.

2. What is the future outlook for market growth?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by expanding genomic testing adoption and increasing demand for targeted cancer therapies.

3. What are the key drivers of market expansion?

Key drivers include rising cancer incidence rates, growing adoption of precision oncology, and technological advancements in next-generation sequencing (NGS) and AI-based analytics.

4. Which challenges hinder market growth?

High testing costs, limited reimbursement coverage, and regulatory complexities pose significant challenges to widespread adoption of cancer tumor profiling solutions.

5. Which regions are leading the market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe, with Asia-Pacific emerging as a high-growth region due to rising awareness.

6. Who are the top companies in the market?

Leading players include Thermo Fisher Scientific, Roche Diagnostics, Illumina, and Quest Diagnostics, who are investing heavily in R&D and strategic partnerships.

7. What future opportunities exist in the market?

Opportunities lie in expanding liquid biopsy applications, integrating AI for predictive analytics, and developing cost-effective profiling solutions for emerging markets.

8. How does technology impact the market?

Next-generation sequencing (NGS) and machine learning are revolutionizing tumor profiling by enabling faster, more accurate biomarker identification and treatment prediction.

9. What is the regulatory landscape like?

Regulatory frameworks are evolving, with the FDA and EMA prioritizing standardized testing protocols and expedited approvals for innovative tumor profiling technologies.

10. What role does liquid biopsy play?

Liquid biopsy is gaining traction as a non-invasive alternative to tissue-based profiling, enhancing patient compliance and enabling real-time cancer monitoring.

Contact for Full Report

Loading report content...

cancer tumor profiling Growth, Trends & Forecast Outlook 2033

Market Snapshot

cancer tumor profiling Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

cancer tumor profiling Segmentation

cancer tumor profiling Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current cancer tumor profiling market size?

2. What is the future outlook for market growth?

3. What are the key drivers of market expansion?

4. Which challenges hinder market growth?

5. Which regions are leading the market?

6. Who are the top companies in the market?

7. What future opportunities exist in the market?

8. How does technology impact the market?

9. What is the regulatory landscape like?

10. What role does liquid biopsy play?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

cancer tumor profiling Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

cancer tumor profiling Segmentation

cancer tumor profiling Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current cancer tumor profiling market size?

2. What is the future outlook for market growth?

3. What are the key drivers of market expansion?

4. Which challenges hinder market growth?

5. Which regions are leading the market?

6. Who are the top companies in the market?

7. What future opportunities exist in the market?

8. How does technology impact the market?

9. What is the regulatory landscape like?

10. What role does liquid biopsy play?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation